
Sirolimus vs tacrolimus in GvHD prophylaxis following haploidentical allo-HCT: a retrospective analysis


**Population:** N = 423


**Primary endpoint:** aGvHD; cGvHD. Secondary endpoints: Neutrophil engraftment; platelet engraftment; non-relapse mortality; relapse; GvHD free relapse-free survival; disease-free survival; overall survival

Eligibility: Undergoing haplo-peripheral hematopoietic stem cell transplantation at 2 U.S. centres (City of Hope Comprehensive Cancer Center and Moffitt Cancer Centre); receiving GvHD prophylaxis for hematologic malignancy between January 2014 and December 2019

## TRIAL DESIGN Retrospective cohort study







GvHD prophylaxis option to tacrolimus combined with PTCy and MMF. **Abbreviations:** aGvHD, acute graft-versus-host disease; allo-HCT, allogenic-hematopoietic cell transplantation; Bu, busulfan; cGvHD, chronic GvHD; CI, confidence interval; Cy, cyclophosphamide; DFS, disease-free survival; Flu, fludarabine; GRFS,

GvHD free relapse-free survival; HR, hazard ratio; MEL, melphalan; MMF, mycophenolate mofetil; NRM, non-relapse mortality;

OS, overall survival; PTCy, posttransplant cyclophosphamide; TAC, tacrolimus; TBI, total body irradiation; SIRO, sirolimus.

This retrospective cohort study demonstrated that sirolimus is a comparable

Elmariah H, et al. Transplant Cell Ther. 2023. Online ahead of print. DOI: 10.1016/j.jtct.2023.11.010



Brought to you by



**Scientific Education Support**